ARTICLE | Clinical News
Trelstar triptorelin pamoate regulatory update
March 22, 2010 7:00 AM UTC
FDA approved a 6-month formulation of 22.5 mg Trelstar triptorelin pamoate from Watson for palliative treatment of advanced prostate cancer. The company plans to launch the product in May. Watson alre...